欧洲当地时间5月14日,诺和诺德宣布,已与美国生物技术公司Septerna达成合作及许可协议,共同开发用于治疗肥胖症、2型糖尿病和其他心脏代谢疾病的口服小分子药物,该协议价值预计高达22亿美元。(文章来源:第一财经)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.